Literature DB >> 16126176

Dynamic expression of Hsp27 in the presence of mutant ataxin-3.

Wei-Hsiu Chang1, Cemal K Cemal, Yung-Hsiang Hsu, Cheng-Liang Kuo, Nobuyuki Nukina, Ming-Hong Chang, Hsiao-Tang Hu, Chuan Li, Mingli Hsieh.   

Abstract

Machado-Joseph disease (MJD)/spinocerebellar ataxia type 3 (SCA3) is an autosomal dominant spinocerebellar degeneration characterized by a wide range of clinical manifestations. The molecular mechanisms underlying the selective neuronal death typical of MJD/SCA3 are unknown. In this study, human SK-N-SH neuroblastoma cells stably transfected with full-length MJD with 78 CAG repeats were assayed for the dynamic expression of Hsp27, known as a suppressor of poly-Q mediated cell death, in the presence of mutant ataxin-3 in different passages of cultured cells. A dramatic decrease of Hsp27 expression was observed in the earlier passage of cultured SK-N-SH-MJD78 cells, however, the later passage of cells showed a significant increase of Hsp27 to almost the same level of the parental cells. Furthermore, immunohistochemical analysis of MJD transgenic mice and post-mortem human brain tissues showed increased expression of Hsp27 compared to normal control brain, suggesting an up-regulation of Hsp27 in the end stage of MJD. However, mutant cells of earlier passages were more susceptible to serum deprivation than mutant cells of later passages, indicating weak tolerance toward stress in cells with reduced Hsp27. While heat shock was used to assess the stress response, cells expressing mutant ataxin-3 displayed normal response upon heat shock stimuli when compared to the parental cells. Taken together, we proposed that during the early disease stage, the reduction of Hsp27 synthesis mitigated the ability of neuron cells to cope with cytotoxicity induced by mutant ataxin-3, triggering the cell death process during the disease progress. In the late stage of disease, after prolonged stressful conditions of polyglutamine cytotoxicity, the increased level of Hsp27 may reflect a dynamic process of the survived cells to unfold and remove mutant ataxin-3. However, this increased Hsp27 still cannot reverse the global dysfunction of cellular proteins due to accumulation of cytotoxic effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16126176     DOI: 10.1016/j.bbrc.2005.08.065

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

Review 1.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

2.  Focused cerebellar laser light induced hyperthermia improves symptoms and pathology of polyglutamine disease SCA1 in a mouse model.

Authors:  Scoty M Hearst; Qingmei Shao; Mariper Lopez; Drazen Raucher; Parminder J S Vig
Journal:  Cerebellum       Date:  2014-10       Impact factor: 3.847

3.  Altered expression of carbonic anhydrase-related protein XI in neuronal cells expressing mutant ataxin-3.

Authors:  Mingli Hsieh; Wei-Hsiu Chang; Chi-Fu Hsu; Isao Nishimori; Cheng-Liang Kuo; Tomoko Minakuchi
Journal:  Cerebellum       Date:  2013-06       Impact factor: 3.847

4.  Treatment with Caffeic Acid and Resveratrol Alleviates Oxidative Stress Induced Neurotoxicity in Cell and Drosophila Models of Spinocerebellar Ataxia Type3.

Authors:  Yu-Ling Wu; Jui-Chih Chang; Wei-Yong Lin; Chien-Chun Li; Mingli Hsieh; Haw-Wen Chen; Tsu-Shing Wang; Chin-San Liu; Kai-Li Liu
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

Review 5.  Transcriptional malfunctioning of heat shock protein gene expression in spinocerebellar ataxias.

Authors:  N Y Macy Huen; S L Alan Wong; H Y Edwin Chan
Journal:  Cerebellum       Date:  2007       Impact factor: 3.648

6.  The protective and therapeutic function of small heat shock proteins in neurological diseases.

Authors:  Sara E Brownell; Rachel A Becker; Lawrence Steinman
Journal:  Front Immunol       Date:  2012-05-01       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.